We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gossypol Reverses Chemo Resistance

By Biotechdaily staff writers
Posted on 08 Aug 2005
Researchers studying the relationship between fatty deposits in the liver (steatosis) and insulin resistance have found that the enzyme mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 (mtGPAT1) plays a key role in the development of insulin resistance and should be considered a target for treatment of diabetes.

Investigators at Yale University (New Haven, CT, USA) genetically engineered a line of mice to lack the gene for production of mtGPAT1. More...
These animals and a control group with normal levels of mtGPAT1 were placed on high-fat diets.

After three weeks, mice lacking mtGPAT1 had markedly lower than normal concentrations of the liver lipid metabolites hepatic triacylglycerol and diacylglycerol. Compared to normal mice, the animals also were protected from hepatic insulin resistance. Furthermore, results published in the July 2005 issue of Cell Metabolism revealed that the mice lacking mtGPAT1 exhibited increased hepatic insulin sensitivity despite an almost 2-fold elevation in levels of hepatic acyl-CoA, a substance previously linked to insulin resistance. This finding suggests that long chain acyl-CoA's do not mediate fat-induced hepatic insulin resistance in this model, and that mtGPAT1 might serve as a novel target for treatment of hepatic steatosis and hepatic insulin resistance.

Senior author Dr. Gerald Shulman, professor of medicine at Yale University, said, "Through noninvasive measurements of hepatic triglyceride content in humans, we have learned that elevated liver fat is fairly ubiquitous in patients with poorly controlled type 2 diabetes. It has been an under-appreciated aspect of the disease.”

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.